Understanding Psychosis and Substance Use
Cracking Addiction20 Joulu 2023

Understanding Psychosis and Substance Use

In this episode of Cracking Addiction, Dr. Ferghal Armstrong and guest Dr. Manu Bhatnagar engage in a deep dive into the complex topic of psychosis, specifically in the context of substance use disorders. With a focus on understanding the nature of psychosis, the impetus behind psychotic experiences, and the differentiating factors between substance-induced psychotic disorders and primary schizophrenia disorders, this episode imparts valuable insights for both healthcare professionals and individuals affected by addiction and mental health issues.

Focus Keyword: Psychosis in Addiction

In this episode of Cracking Addiction, Dr. Manu Bhatnagar and Dr. Ferghal Armstrong dissect the nature of psychosis, emphasizing its status as a symptom rather than a standalone illness. They highlight the potential influences of social and cultural contexts on the diagnosis of psychosis, shedding light on the impact of societal trends and media portrayals on the manifestation of psychotic experiences. The discussion delves into the potential causes of psychosis, including the interplay of genetic, environmental, and substance-related factors.

Learning Outcomes:

1. Understanding the Multifaceted Nature of Psychosis: Dr. Bhatnagar provides a comprehensive overview of psychosis, defining it as a disruption of thought, perception, and cognition. This highlights the diversity of psychotic experiences and the importance of individual past experiences in shaping these manifestations. The discussion offers a nuanced understanding of psychosis as a complex interplay of factors, paving the way for more holistic approaches to addressing psychotic symptoms.

2. Differentiating Substance-Induced Psychotic Disorders: The episode elucidates the distinction between substance-induced psychotic disorders, particularly those triggered by stimulants and cannabis, and primary schizophrenia disorders. The emphasis on psychomotor agitation as a hallmark of substance-induced psychosis provides a valuable framework for clinicians to differentiate these conditions, informing targeted interventions.

3. Longitudinal Assessment and Treatment Implications: The speakers underscore the significance of longitudinal assessment in distinguishing substance-induced psychosis from primary schizophrenia disorders. This insight carries profound implications for treatment, as the potential resolution of symptoms with abstinence underscores the importance of addressing substance use in managing psychotic experiences.

Actionable Takeaways:

1. Embrace a Holistic Understanding: Recognize the multifactorial nature of psychosis, encompassing genetic predispositions, environmental influences, and substance-related triggers. This broader perspective can inform more comprehensive treatment strategies, taking into account the diverse factors contributing to psychotic experiences.

2. Heightened Clinical Vigilance: Develop a heightened awareness of the hallmarks of substance-induced psychotic disorders, such as psychomotor agitation and acute onset in the context of substance use. This keen clinical vigilance can aid in accurate differential diagnosis and tailored interventions for individuals presenting with psychotic symptoms.

3. Prioritize Longitudinal Assessment: Prioritize longitudinal assessment, particularly in cases of suspected substance-induced psychosis, to discern the potential impact of substance use on psychotic experiences. This approach underscores the importance of addressing substance use disorders in managing psychosis and promoting long-term recovery.

Jaksot(218)

LAIB - Sublocade

LAIB - Sublocade

Cracking Addiction discusses Sublocade one of the LAIB preparations available and how to commence, maintain and manage any dose changes or complications associated with Sublocade.Sublocade is a long acting injectable buprenorphine (LAIB) manufactured by Invidior that uses the “Atrigel” system to provide for a sustained and prolonged delivery of buprenorphine into the systemic circulation after subcutaneous injection.Discussions and comments in our videos are for informational purposes only and should not replace the advice of your medical professional. Please consult with your doctor before making any changes to your medical treatment or lifestyle.Latest Blogshttps://www.meducate.com.au/blogAbout Meducate ®Meducate provides online education for doctors, clinicians, health professionals and the public.See the website to browse the many different talks and courses available https://www.meducate.com.au

9 Helmi 202215min

LAIB - Buvidal

LAIB - Buvidal

Cracking Addiction discusses Buvidal one of the LAIB preparations available and how to commence, maintain and manage any dose changes or complications associated with Buvidal.Buvidal is a long acting injectable buprenorphine (LAIB) preparation manufactured by Camurus and uses “FluidCrystal” technology to provide for a sustained and prolonged delivery of buprenorphine into the systemic circulation after subcutaneous injection.

3 Helmi 202217min

LAIB Special Circumstances

LAIB Special Circumstances

Cracking Addiction discusses some of the special or difficult circumstances of prescribing LAIBs including intoxicated patients, pregnant patients, patients with chronic disease, patients with acute pain and our management strategies in these situations.

26 Tammi 202219min

LAIB first dose considerations

LAIB first dose considerations

Episode 23 of Cracking Addiction explores commencement of patients on LAIB, side effects and risks of LAIB, discussion about precipitated withdrawal and when and how to review patients

20 Tammi 202220min

Long Acting Injectable Buprenorphine (LAIB) - Introduction

Long Acting Injectable Buprenorphine (LAIB) - Introduction

An Introduction to Long Acting Injectable Buprenorphine (LAIB)Long acting injectable buprenorphine (LAIB) are long acting buprenorphine depot preparations that are injected subcutaneously and provide patients with a sustained release of buprenorphine for the duration of the depot preparation. Currently, two LAIB products are available for the Australian market. They differ in their formulations, administration and pharmacology.See blog for further informationhttps://www.meducate.com.au/blogAbout Meducate ®Meducate provides online education for doctors, clinicians, health professionals and the public.See the website to browse the many different talks and courses availablehttps://www.meducate.com.au

12 Tammi 202218min

Methadone pharmacokinetics and interactions

Methadone pharmacokinetics and interactions

Episode 21 of Cracking Addiction explores methadone pharmacokinetics, breakdown and interactions within the body and interactions with other drugs.Methadone is a drug with a wide variability in its absorption with oral bio-availability ranges from 35% to 100%. This is a significant amount of variability and explains why the same dose of Methadone can impact different patients differently. Methadone is metabolised within the liver by the cytochrome P450 enzymes but mainly 3A4. There is a 17-fold inter-individual variation of methadone blood concentration for a given dosage and variations in metabolism account for a large part of this variation. Kinetic interactions influenced by the CYP 450 enzyme can affect plasma methadone levels.• Inducers of CYP450 can• Accelerate the metabolism of methadone• lower methadone plasma levels• Precipitate opioid withdrawal • Inhibitors of CYP450 can • Slow the metabolism of methadone• Increase plasma levels• Produce opioid toxicity (sedation, overdose)Methadone is excreted renally with approximately 10% of drug renally eliminated unchanged. Renal excretion of methadone urinary pH dependent with increased Methadone excretion noted at pH less than 6 and decreased Methadone excretion at higher pH levels.About Meducate ®Meducate provides online education for doctors, clinicians, health professionals and the public.See the website to browse the many different talks and courses availablehttps://www.meducate.com.au

22 Joulu 202116min

Methadone pharmacology and induction

Methadone pharmacology and induction

Episode 20 of Cracking Addiction explores methadone, its origins, the pharmacology behind methadone and how to commence a patient on Methadone.Methadone is a synthetic long acting mu receptor agonist suitable for the treatment of opioid use disorder. Methadone has a longer plasma half life than morphine (average 22 hours (15-32 hours) vs 2 hours for morphine) which permits once daily supervised dosing.https://www.meducate.com.au/blogAbout Meducate ®Meducate provides online education for doctors, clinicians, health professionals and the public.See the website to browse the many different talks and courses availablehttps://www.meducate.com.au

15 Joulu 202122min

Opioid use disorder Post Partum

Opioid use disorder Post Partum

Episode 19 of Cracking Addiction explores the management of opioid use disorder in the post partum period.Post birth the patient's usual oral methadone dose can be continued in the peripartum and post partum period. There is a theoretical concern in the postpartum period of over-sedation as methadone levels may increase as plasma volume and hepatic clearance normalise post the delivery of the child. Latest Blogshttps://www.meducate.com.au/blogAbout Meducate ®Meducate provides online education for doctors, clinicians, health professionals and the public.See the website to browse the many different talks and courses availablehttps://www.meducate.com.au

9 Joulu 202111min

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
tiedenaiset-podcast
voi-hyvin-meditaatiot-2
psykopodiaa-podcast
rss-pitaisko-erota
vakeva-elama-viisaampi-mieli-vahvempi-keho
meditaatiot-suomeksi
selvin-pain
rss-kuumilla-aalloilla
rss-uplevel-by-sonja-hannus
rss-nautinto
terapiassa
junnut-pelissa
rss-en-saa-unta
rss-rentoudu-podcast-rentoutumiseen-hanna-viljanmaa
paritellen
selviytyjat-tarinoita-elamasta
fitnessvastaanotto
rss-pt-paahtio
rss-duodecim-lehti